Biogen has announced it will acquire Nightstar Therapeutics for around $800m, providing the pharma giant with a pipeline of gene therapy candidates for ophthalmology.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.
Johnson and Johnson has vowed to become the first pharmaceutical giant to add its medicine prices to television adverts, starting in March 2018. The company said it will list not only product price before rebates or discounts, as well as potential out-of-pocket costs which patients will pay.
With so many talks and panels occurring across our four stages and Live Lounge, we understand that it can be pretty hard to pick out the most unmissable discussions at the festival this year. Given the conundrum, we thought we’d help out! We’ve selected a couple of talks and panels occurring across the two days which we think will be incredibly interesting and enormously informative for a whole range of people.
A new deal created by the Coalition for Epidemic Preparedness Innovations (CEPI) will use $8.4m to facilitate development of a vaccine platform to fight unknown pathogens. Under the deal, Imperial College London will work to create a self-amplifying RNA vaccine platform, which can then be made to rapidly develop anti-pathogen vaccines.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
UC San Francisco scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.
APP, the gene responsible for making beta-amyloid in the brain, may be able to reshuffle its own DNA, scientists from Sanford Burnham Prebys Medical Discovery Institute in California have claimed. This development could explain why most drugs to treat Alzheimer’s, which are designed to remove beta-amyloid protein build-ups in the brain, have proven ineffective in clinical trials.
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.